Emyria Expands drug candidate library with third batch of MDMA-inspired analogues
- Emyria (EMD) progresses its drug discovery and development of the company’s preclinical MDMA analogue medicine program with program partner UWA
- The partnership has created a third batch comprising of 19 novel MDMA analogues which have been characterised and sent for screening
- The design of the batch is led by Professor Matt Piggott and his team at UWA and was guided by the results received from the screening of the first two batches
- Managing Director Dr Michael Winlo says the company had identified three therapeutic areas to target following its initial screening results
- Shares in the company are down 4.55 per cent to close at 21 cents
